Search clinical trials for: Licarbazepine

Total 126 results

Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Novartis

Completed

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

Bipolar Disorder

Austria, Canada, Czech Republic, Germany, Peru, Russian Federation, Slovakia, South Africa, Ukraine, Venezuela, United States, Colombia, Guatemala
Novartis

Completed

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine

Healthy

Czech Republic
Novartis

Completed

Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine

Healthy

Czech Republic
Novartis Pharmaceuticals

Completed

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Bipolar Disorder

United States, France, Russian Federation
Novartis

Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder

Bipolar I Disorder
Novartis

Completed

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

Bipolar I Disorder

United States
Novartis Pharmaceuticals

Completed

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Bipolar Disorder

United States, Austria, Canada, Colombia, Czech Republic, Germany, Guatemala, Peru, Russian Federation, Slovakia, South Africa, Ukraine, Venezuela
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Novartis Pharmaceuticals

Completed

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Bipolar Disorder

United States
Bial - Portela C S.A.

Terminated

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

BIPOLAR I DISORDER
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Sunovion

Completed

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Epilepsy

United States, Bulgaria, Czech Republic, Serbia, Ukraine
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Collaborative Care Initiative, LLC
Dauten Family Center for Bipolar Treatment Innovation, Massachusetts Gen...

Unknown

Comparison of Two Forms of Oxcarbazepine for the Treatment of Bipolar Depression

Bipolar Depression | Treatment Effectiveness | Measure-based Guidance

United States
Desitin Arzneimittel GmbH
FGK Clinical Research GmbH

Terminated

EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy

Partial Epilepsy

Germany
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Unknown

ZEBinix® Retention Rate in Epilepsy in Elderly Patients (ZEBRE)

Epilepsy | Aging | Epilepsy; Seizure | Aging Disorder

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Partial Epilepsy

Belgium
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Sidney Kimmel Comprehensive Cancer Center at Johns...
Prostate Cancer Foundation

Completed

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

Prostate Cancer

United States
Novartis Pharmaceuticals

Completed

Pediatric Epilepsy Study

Epilepsy | Epilepsies, Partial

United States, Germany, Brazil, Mexico
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Novartis Pharmaceuticals

Completed

Pediatric Epilepsy Study

Epilepsy

United States, Germany, Brazil, Mexico
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Supernus Pharmaceuticals, Inc.

Completed

Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Partial Epilepsy

United States, Poland, Bulgaria, Romania, Canada, Russian Federation, Mexico, Croatia
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Sunovion

Completed

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Epilepsy With Partial On-set Seizures

United States, Canada
Supernus Pharmaceuticals, Inc.

Approved for marketing

Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

Epilepsy

United States
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours

Epilepsy

Romania, Slovakia

3

Subscribe